

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant(s):** Helen G. Durkin, et al.

**Examiner:** Dameron L. Jones

**Serial No:** 10/523,856

**Art Unit:** 1618

**Filed:** October 18, 2005

**Docket:** 15727

**For:** METHOD FOR MONITORING THE  
EFFECTIVENESS OF TETRACYCLINE  
IN THE TREATMENT OF ASTHMA

**Dated:** February 13, 2008

**Confirmation No:** 4411

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. §§1.56, 1.97 and 1.98**

Sir:

Applicants, in order to meet their duty of disclosure, set forth at 37 C.F.R. §1.56, submit herewith and list on the attached electronic form PTO/SB/08, those references which they deem relevant to the claims of the present application.

The relevant references are as follows:


1. International Publication No. WO 94/29696, published December 22, 1994; and
2. SAMPSON, HUGH ET AL., Human IgE Synthesis *In Vitro*: A Reassessment, The Journal of Immunology, September 1981, pp. 829-834, Vol. 127, No. 3.

---

**CERTIFICATE OF ELECTRONIC FILING**

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website, on **February 13, 2008**.

Dated: **February 13, 2008**

  
\_\_\_\_\_  
Mark Cohen

Consideration of this Information Disclosure Statement is respectfully requested, since the above-cited references were cited in a Search Report dated January 15, 2008 received from the European Patent Office in connection with the corresponding PCT application. Applicants are submitting a copy of the Search Report. The relevance of the above-identified references has been presented in the Search Report.


It is noted that the following references, also cited in said Search Report, have been previously filed with the United States Patent and Trademark Office in an Information Disclosure Statement dated November 30, 2007, thus need not be cited herewith:

- A. International Publication No. WO 03/099270, published December 4, 2003;
- B. U.S. Patent Application Publication No. 2003/195184, dated October 16, 2003,  
issued to Mitchell et al.;
- C. International Publication No. WO 03/061767, published July 31, 2003;
- D. International Publication No. WO 03/005971, published January 23, 2003;
- E. International Publication No. WO 92/16226, published October 1, 1992;
- F. HAHN, DAVID, Is There a Role for Antibiotics in the Treatment of Asthma?,  
Biodrugs, 2000, pp. 349-354, Vol. 14, Auckland, NZ; and
- G. MENON ET AL., Tetracycline Asthma a Case Report, Clinical and Experimental  
Allergy, Blackwell Scientific Publications, 1997, pp. 285-290, Vol. 7, London,  
GB.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

In the event that an action on the merits crosses in the mail when submitting this Information Disclosure Statement, applicants hereby state, "That each item of information contained herein was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement."

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Mark J. Cohen". The signature is fluid and cursive, with the first letters of each word being capitalized and prominent.

Mark Cohen  
Registration No. 32,211

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343  
MC:vh